Want to see FBLG full AI Analyst Report?
FBLG Stock Chart & Stats
$0.71
-$0.08(-11.92%)
At close: 4:00 PM EDT
$0.71
-$0.08(-11.92%)
Day’s Range― - ―
52-Week Range$0.62 - $13.17
Previous Close$0.67
Volume161.72K
Average Volume (3M)978.93K
Market Cap
$4.26M
Enterprise Value$5.98
Total Cash (Recent Filing)$3.52M
Total Debt (Recent Filing)$1.34M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.48
Shares Outstanding6,080,560
10 Day Avg. Volume1,423,641
30 Day Avg. Volume978,931
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-4.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance Sheet / Lower LeverageMaterial reduction in leverage and lower total debt meaningfully strengthens capitalization. A healthier balance sheet extends runway for R&D, reduces near-term refinancing pressure, and improves bargaining power with partners and investors — a durable structural improvement for a pre-commercial biotech.
Strengthened Scientific LeadershipAdding a high-profile scientist with genomics and translational experience boosts credibility and governance. Her long-term involvement can accelerate clinical strategy, attract collaborators, and improve oversight of R&D programs — a persistent enhancement to scientific and institutional capital.
Established Equity Financing ChannelsMaintained access to multiple equity funding mechanisms (ATM and recent private placement) provides a structural liquidity outlet. That flexibility supports ongoing development spending, reduces short-term cash shock risk, and allows staged financing tied to program milestones, albeit with dilution trade-offs.
Bears Say
No Revenue; Widening Net LossesPersistent lack of product revenue and expanding net losses reflect a pre-commercial profile that cannot self-fund operations. Over the medium term this increases reliance on external capital, heightens execution risk for the pipeline, and limits reinvestment capacity absent successful financing or partnerships.
Sustained Negative Operating Cash FlowConsistent negative operating and free cash flow indicates structural cash burn that outpaces internal generation. This necessitates repeated financings, creates dilution pressure, and can force program prioritization or cutbacks if market funding tightens, undermining long-term program continuity.
Nasdaq Delisting RiskActive delisting proceedings pose a material structural risk: loss of listing would reduce liquidity, restrict access to institutional capital and equity markets, complicate raising funds, and impair credibility with partners, materially constraining strategic options over months.
FibroBiologics, Inc. News
FBLG FAQ
What was FibroBiologics, Inc.’s price range in the past 12 months?
FibroBiologics, Inc. lowest stock price was $0.62 and its highest was $13.17 in the past 12 months.
What is FibroBiologics, Inc.’s market cap?
FibroBiologics, Inc.’s market cap is $4.26M.
When is FibroBiologics, Inc.’s upcoming earnings report date?
FibroBiologics, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 107 days.
How were FibroBiologics, Inc.’s earnings last quarter?
FibroBiologics, Inc. released its earnings results on Jul 30, 2026. The company reported -$0.656 earnings per share for the quarter, beating the consensus estimate of -$0.93 by $0.274.
Is FibroBiologics, Inc. overvalued?
According to Wall Street analysts FibroBiologics, Inc.’s price is currently Overvalued.
Does FibroBiologics, Inc. pay dividends?
FibroBiologics, Inc. does not currently pay dividends.
What is FibroBiologics, Inc.’s EPS estimate?
FibroBiologics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does FibroBiologics, Inc. have?
FibroBiologics, Inc. has 6,080,560 shares outstanding.
What happened to FibroBiologics, Inc.’s price movement after its last earnings report?
FibroBiologics, Inc. reported an EPS of -$0.656 in its last earnings report, beating expectations of -$0.93. Following the earnings report the stock price went up 9.939%.
Which hedge fund is a major shareholder of FibroBiologics, Inc.?
Currently, no hedge funds are holding shares in FBLG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
FibroBiologics, Inc.
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
FBLG Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Curis
―
Synlogic
―
Lexaria Bioscience
―
Processa Pharmaceuticals
―